Case Studies & Whitepapers2025-02-10
Efficacy and Safety - Guidelines for Clinical In-use Stability Studies of ADCs Download
Antibody-drug
conjugates (ADCs) consist of three parts: antibody, linker, and payload. This
special combination enables ADCs to selectively target tumor cells and release
cytotoxic drugs, but they face many stability challenges during manufacture,
storage, and clinical use. In this paper, the drug product development team at Porton
(hereinafter referred to as "we") discusses the necessary clinical
in-use stability studies for ADCs.
At
present, the 16 ADCs currently on the market employ intr
More
News
More
Case Studies & Whitepapers2026-09-25
Dual-Payload Conjugates: Addressing the CMC Challenges of a New Therapeutic Approach
Dual-payload conjugates—two mechanistically distinct payloads carried on a single targeting vehicle—represent the next technological frontier beyond conventional ADCs.
Case Studies & Whitepapers2026-09-21
PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
This article offers a systematic overview of PMO drug technology covering underlying principles, manufacturing workflows, and therapeutic prospects.
